Inside the Nanyang Biologics SPAC Deal: Terms, Risks, Verdict
Nanyang Biologics is an AI-driven drug discovery and biotechnology company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The deal is pitched at a $1.5 billion valuation, but shareholders should watch redemption risk, dilution, and whether the pre-revenue biotech can convert its platform story into clinical progress.
Nanyang Biologics is an AI-driven drug discovery and biotechnology company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The deal is pitched at a $1.5 billion valuation, but shareholders should watch redemption risk, dilution, and whether the pre-revenue biotech can convert its platform story into clinical progress.
Deal at a Glance
SPAC partner: RF Acquisition Corp II
SPAC ticker (trades now): RFAI
Expected post-merger ticker: NYB
Implied valuation: $1.5B
Expected close: Q1-Q2 2026
Est. first trading date: mid-2026
Deal status: Announced
Source filing: SEC 425 (2026-08-20)
Company Overview
Nanyang Biologics Pte. Ltd. (NYB) describes itself as an AI-driven drug discovery and biotechnology company that combines artificial intelligence with natural compounds and traditional medicine to identify drug candidates. Its flagship platform is Vecura™ AI, powered by a proprietary Drug-Target Interaction Graph Neural Network (DTIGN), which the company says helps translate large biochemical spaces into feasible drug candidates.
The company says its pipeline includes five molecules across oncology, cardiovascular, and mental health, including NB-A002, which it describes as a first-in-class targeted therapy for cancers with compromised DNA damage response (DDR). NYB is anchored in Singapore and says it is building one of the world’s largest AI-curated natural compound libraries with partners including NVIDIA, Hewlett Packard Enterprise, Equinix, and research institutions such as Nanyang Technological University Singapore. The filing materials characterize the drug-development vertical as pre-revenue and in an early clinical development phase.
Industry-wise, NYB is playing in the crowded but high-upside intersection of AI drug discovery, oncology biotech, and natural-compound-based therapeutics. The company’s own materials frame the opportunity around oncology, cardiovascular, mental health, inflammation, and nutraceuticals, with a particular emphasis on DDR-related cancer therapy.
The SPAC Deal
The transaction values Nanyang Biologics at $1.5 billion. In the F-4/A, the exchange mechanics are tied to a formula that divides $1,500,000,000 by $10.00 by the number of company shares outstanding immediately prior to closing, which is the clearest primary-source statement of the implied equity value. I did not find a separately stated enterprise value bridge in the excerpts reviewed.
On the SPAC side, RF Acquisition Corp II trades today as RFAI. As of September 26, 2025, the trust account held at least $122,454,702.09, including about $3,633,863 of deferred underwriting commissions and other fees held in trust. That trust can be used for redemptions, so the real cash delivered at close depends on how many public shares are redeemed; the filing excerpts reviewed do not disclose actual or expected redemption levels. I found no disclosed PIPE or other committed third-party financing in the materials reviewed, which leaves the deal more exposed to redemptions than a fully backstopped transaction.
The accessible excerpts also do not provide a clean sponsor-promote summary or a full warrant dilution table, so warrant overhang and sponsor dilution are not fully quantified from the primary-source text I could retrieve. The deal was announced with an expected close in Q1 or Q2 2026, and the SEC F-4 was filed on March 19, 2026 with a later amendment, which means the transaction was still in process in the latest filing set reviewed. If it closes on the expected schedule, the combined company is expected to trade on Nasdaq under the reserved ticker NYB, likely in the mid-2026 window.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
For NYB, the SPAC route offers a faster path to the public markets than a traditional IPO and gives the company a capital-markets platform while it is still early in development. That matters for a pre-revenue biotech because the story is built around platform potential, pipeline optionality, and future clinical milestones rather than current sales.
The structure also allows the company to present projections and valuation work in the merger materials, which is a common SPAC advantage for companies that are still scaling. The tradeoff is that investors are underwriting execution, clinical progress, and financing quality more than current operating results.
Financial Highlights
The clearest historical financial data disclosed in the filing materials is net loss of approximately $(3.56) million for the year ended September 30, 2024 and $1.34 million for the year ended September 30, 2025. The company’s drug-development vertical is explicitly described as pre-revenue and in an early clinical development phase, and I did not find disclosed revenue in the excerpts reviewed.
The filing materials also include forward-looking projections and valuation assumptions, but those should be treated as projections rather than audited results. One valuation method referenced EV/revenue multiples ranging from 4.05x to 6.07x for a peer group, but the company’s current operating scale remains early and the filing excerpts do not disclose a precise cash balance or runway figure.
Risk Factors
The biggest de-SPAC risk is redemption risk. RF Acquisition Corp II had at least $122.5 million in trust as of September 26, 2025, but the amount that actually reaches the combined company depends on how many public shareholders redeem. With no PIPE disclosed in the materials reviewed, the deal has less financing cushion if redemptions are heavy.
Dilution is another key issue. SPAC deals typically carry sponsor promote and warrant overhang, and while the excerpts reviewed do not fully quantify those items, shareholders should assume dilution pressure until the final pro forma capitalization is clear. The business itself is also early-stage: NYB is pre-revenue in its drug-development vertical, so clinical setbacks, regulatory delays, or weaker-than-expected data could hit the equity hard. The deal could also be delayed if shareholder approval or SEC review takes longer than expected, and the filing materials do not show a completed close yet.
Comparable Public Companies
The filing’s own valuation work points to public biotechnology companies focused on oncology drug development as the peer set, and it also references EV/revenue multiples of 4.05x to 6.07x. That suggests the market is likely to judge NYB against a mix of early-stage biotech and AI-enabled discovery names rather than mature pharma companies.
Comparable public names investors may watch for context include Recursion Pharmaceuticals (RXRX), Schrödinger (SDGR), and Absci (ABSI), along with broader oncology biotech peers such as Iovance Biotherapeutics (IOVA). These stocks tend to trade on pipeline milestones, cash runway, and sentiment around platform technology rather than near-term earnings, and multiples can swing sharply with clinical updates and risk appetite.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
This is a classic high-upside, high-uncertainty de-SPAC setup. The bull case is straightforward: NYB is pitching a differentiated AI-plus-natural-compounds platform, a five-molecule pipeline, and exposure to oncology and other large therapeutic markets, all wrapped in a Singapore-based deep-tech story that fits the SPAC’s stated Asia-focused mandate.
What shareholders should watch next is not just the vote, but the quality of the cash that survives to close. The combination of a $1.5 billion headline valuation, a $122.5 million trust account, no disclosed PIPE in the reviewed materials, and an early-stage pre-revenue profile means the post-merger stock will likely be driven by redemption outcomes, dilution, and whether the company can keep advancing its pipeline. If the deal closes on the expected schedule, the first trading window looks like mid-2026 under NYB; that is when the market will decide whether this is a real biotech platform or just another SPAC story.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
